Clinical trials: Mycobacterium
Tuberculosis, Pulmonary
Atorvastatin to Reduce Inflammation After Tuberculosis Treatment Completion
This is a proof-of-concept phase IIB, double-blind, randomized, placebo-controlled trial to evaluate the safety and efficacy of 40 mg atorvastatin to reduce persistent lung inflammation after successful TB treatment completion in…
- Trial name
- StatinTB (NCT04147286)
- Testing
- Atorvastatin 40mg
- Where
- South Africa
- Volunteers
- 220 people
- Sponsor
- University of Cape Town
Tuberculosis, Multidrug-Resistant
Expand New Drugs for TB [endTB]
This observational study will examine the safety and efficacy of bedaquiline and delamanid used (individually, not together) in routine, multidrug regimens for treatment of MDR-TB.
- Trial name
- NCT03259269
- Testing
- This is a non-intervention observational study
- Where
- 16 sites in Armenia, Bangladesh and 12 more
- Volunteers
- 2,804 people
- Sponsor
- Partners in Health
Pneumonia, Pulmonary Tuberculosis
Interferon Gamma for Drug Resistant Tuberculosis
This study will determine what dose of recombinant interferon-gamma is safe and effective for treating multiple drug-resistant tuberculosis.
- Trial name
- NCT00001407
- Testing
- Interferon Gamma
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis
Linezolid to Treat Extensively-Drug Resistant Tuberculosis
This study, conducted in Masan and Seoul, South Korea, investigated the effectiveness of linezolid (LZD) in treating patients with extensively drug resistant tuberculosis (XDR TB).
- Conditions
- Pulmonary Tuberculosis, Multidrug Resistant Tuberculosis, Extensively Drug Resistant Tuberculosis
- Trial name
- NCT00727844
- Testing
- Immediate Start Linezolid, Delayed Start Linezolid
- Where
- 2 sites in South Korea
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Isolated Mediastinal Lymphadenopathy, Sarcoidosis
A Clinical tRial of Endobronchial Ultrasound for the Diagnosis of MEDiastinal lymphadenopathY (REMEDY)
Enlarged glands in the chest (mediastinal lymphadenopathy) is a common problem and may have a variety of different causes. In the past an operation (mediastinoscopy) was required to diagnose the glands.
- Conditions
- Isolated Mediastinal Lymphadenopathy, Sarcoidosis, Tuberculosis, Lung Cancer
- Trial name
- REMEDY (NCT00932854)
- Testing
- EBUS
- Where
- United Kingdom
- Volunteers
- 75 people
- Sponsor
- University College London Hospitals
Post-COVID / Long-COVID
SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)
This placebo-controlled, randomized, blinded, two-arm phase II study will test the safety and potential efficacy of the targeted mAb, Sipavibart (formerly AZD3152) in patients with Long COVID.
- Trial name
- Monoclonal (NCT07021794)
- Testing
- Sipavibart
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Nancy Klimas
Protective Effect in TB-DIH, TB-DIH Means: Drug Induced Liver Function Abnormalities
The Protective Effect for Liver Organ in Patients With Anti-TB Drugs Using of Acetylcysteine (NAC)
Animal studies have shown that INH-RIF-induced oxidative injury can be prevented by supporting the cellular antioxidant defense mechanism by N-acetylcysteine (NAC).
- Trial name
- NCT02889757
- Testing
- Acteylcysteine
- Where
- Taiwan
- Volunteers
- 400 people
- Sponsor
- Far Eastern Memorial Hospital
Chronic Obstructive Pulmonary Disease (COPD), TB - Tuberculosis
COPD-PTB Screening Trial in Henan, China
The goal of this trial is to evaluate the effectiveness of an active case-finding (ACF) strategy for detecting pulmonary tuberculosis (PTB) among patients with chronic obstructive pulmonary disease (COPD) in primary care settings…
- Trial name
- NCT07706972
- Testing
- ACF strategy
- Volunteers
- 25,000 people
- Sponsor
- Henan Provincial People's Hospital
Tuberculosis
A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG
A new, more specific skin test to detect tuberculosis has been developed by Statens Serum Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a positive test result will show as redness and/or…
- Trial name
- TESEC-03 (NCT01242475)
- Testing
- C-Tb, 2 TU Tuberculin PPD RT 23 SSI
- Where
- United Kingdom
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Tuberculosis, Pulmonary
A New Treatment for Primary Smear-positive Pulmonary Tuberculosis With Interleukin-2
The purpose of the study is to compare the efficacy and safety of standard chemotherapy regimen 2HRZE/4HR plus IL-2 and standard regimen 2HRZE/4HR for newly diagnosed smear positive pulmonary tuberculosis.
- Trial name
- NCT04766307
- Testing
- Interleukin-2
- Where
- 16 sites in China
- Volunteers
- 1,100 people
- Sponsor
- Beijing Chest Hospital
Tuberculosis
Development of Molecular Diagnostic Platform for Tuberculosis
This study evaluates new technique for diagnosis of tuberculosis. Among patients who are suspected with tuberculosis, participants will be tested conventional method including Xpert TB/RIF assay, and new diagnostic technique…
- Trial name
- NCT04734236
- Testing
- New technique vs Xpert
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Asan Medical Center
HIV Infections, Neonatal Infection
Immune Response to BCG Vaccination in Neonates Born to HIV and LTBI Infected and Non-infected Mothers
Maternal infections affect the basal immune status of neonates. One of the possible mechanism is the fetomaternal microchimerism, in which some cells and active substances are exchanged bi-directionally between maternal and fetal…
- Conditions
- HIV Infections, Neonatal Infection, LTBI - Latent Tuberculosis Infection, Immune Tolerance
- Trial name
- IMMUNEO (NCT03383211)
- Testing
- RNAseq
- Where
- 2 sites in Moldova
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- George Washington University
Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis
Novel Triple-dose Tuberculosis Retreatment Regimen
To determine if a high-dose first-line regimen is non-inferior (non-inferiority margin 10%) in terms of safety to the same regimen at regular dosing, in previously treated patients with rifampicin-susceptible recurrent…
- Conditions
- Multidrug-resistant Tuberculosis, Pulmonary Tuberculosis, Tuberculosis, Resistance to Tuberculostatic Drugs
- Trial name
- Tri-Do-Re (NCT04260477)
- Testing
- 6EH³R³Z, 6EHRZ
- Where
- Niger
- Volunteers
- 370 people
- Sponsor
- Institute of Tropical Medicine, Belgium
MAC Lung Disease, Treatment Refractory MAC Lung Disease
ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension
This clinical trial is designed to compare the efficacy and safety of Clofazimine Inhalation Suspension versus placebo when added to guideline-based therapy (GBT)
- Conditions
- MAC Lung Disease, Treatment Refractory MAC Lung Disease, Mycobacterium Infections, Nontuberculous
- Trial name
- ICoN-1 (NCT06418711)
- Testing
- Clofazimine Inhalation Suspension
- Where
- 99 sites in United States, Australia and 3 more
- Volunteers
- 132 people
- Sponsor
- Mannkind Corporation
Tuberculosis, TB Infection
A Phase I Study of Lipovaxin Tuberculosis Vaccine in Adult Healthy Populations
A Phase I, Double-Blind, Randomized, Placebo Controlled Trial to Evaluate Safety and Immunogenicity of Lipovaxin Tuberculosis Vaccine (Bio Farma) in Healthy Populations Aged 18-40 Years in Indonesia
- Trial name
- NCT07647107
- Testing
- LipovaxinS4-EAH (Middle Dose), LipovaksinS4-EAH (High Dose)
- Where
- Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- PT Bio Farma
Tuberculosis, Multidrug-resistant
Biomarkers for Therapy Response in Drug-resistant Tuberculosis
Multi-center, observational, prospective cohort study including patients with multidrug-resistant tuberculosis at different sites in Germany. The aim the study is the identification of biomarkers for therapy response.
- Trial name
- NCT02597621
- Testing
- no intervention
- Where
- Germany
- Volunteers
- 192 people, healthy volunteers welcome
- Sponsor
- Research Center Borstel
Non-Tuberculous Mycobacteria Pulmonary Disease, Bronchiectasis
Health Impact of Non-Tuberculous Mycobacteria Pulmonary Disease (NTM-PD)
Nontuberculous mycobacteria (NTM) are environmental organisms found in soil and water. The majority do not cause human disease. When they do, this is mostly as a chronic lung infection in people with long-term lung problems such…
- Trial name
- NCT07192705
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- University College, London
Tuberculosis
Effects of Vitamin D Supplementation on Antimycobacterial Immunity
The purpose of this study is to determine how vitamin D supplementation (ergocalciferol) affects the immune response to mycobacterial infection.
- Trial name
- NCT00157066
- Testing
- Ergocalciferol
- Where
- United Kingdom
- Volunteers
- 230 people
- Sponsor
- Barts & The London NHS Trust
Smoking Cessation, Tuberculosis
A Controlled Smoking Cessation Trial and Prospective Cohort Study of Tuberculosis (TB) Treatment Outcomes
The primary focus of this intervention trial is to understand the effect of quitting smoking on TB treatment outcomes. The investigators will compare a cessation strategy based on guidelines recommended by the World Health…
- Trial name
- NCT02238405
- Testing
- Intensive anti-smoking counseling
- Where
- Pakistan
- Volunteers
- 350 people
- Sponsor
- Johns Hopkins University
Patients on Dialysis
Comparing Consistency of QuantiFERON-TB Gold Plus and QuantiFERON-TB Gold for Latent Tuberculosis in Dialysis Population
In patients receiving long term dialysis, using new generation of QuantiFERON-TB Gold Plus can have less result variability in inter-experiment and serial follow up in comparing with QuantiFERON-TB Gold In-tube.
- Trial name
- NCT02782494
- Testing
- Examination of latent TB by QuantiFERON-TB
- Where
- Taiwan
- Volunteers
- 200 people
- Sponsor
- National Taiwan University Hospital